Gene-targeted versus broad-spectrum therapies in ALS: comparative lessons and strategic outlook
- 6 February 2026
- journal article
- Published by Elsevier in Journal of Genetics and Genomics
- Vol. 53 (7) , 1159-1179
Abstract
No abstract availableKeywords
Funding Information
- National Key Research and Development Program of China (2021ZD0202500)
- National Key Research and Development Program of China (2024YFA1108000)
- National Natural Science Foundation of China (32130035)
- National Natural Science Foundation of China (2024CSJZN0600)
- Changping Laboratory
This publication has 210 references indexed in Scilit:
- Serum levels of glial fibrillary acidic protein in patients with amyotrophic lateral sclerosisAnnals of Clinical and Translational Neurology, 2022
- Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral SclerosisJAMA Neurology, 2022
- Schwann cells orchestrate peripheral nerve inflammation through the expression of CSF1, IL‐34, and SCF in amyotrophic lateral sclerosisGlia, 2019
- Repeated Intrathecal Mesenchymal Stem Cells for Amyotrophic Lateral SclerosisAnnals of Neurology, 2018
- Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral SclerosisJAMA Neurology, 2016
- TARDBPandFUSMutations Associated with Amyotrophic Lateral Sclerosis: Summary and UpdateHuman Mutation, 2013
- Extracellular aggregated Cu/Zn superoxide dismutase activates microglia to give a cytotoxic phenotypeGlia, 2012
- ALSoD: A user-friendly online bioinformatics tool for amyotrophic lateral sclerosis geneticsHuman Mutation, 2012
- Stem cell technology for neurodegenerative diseasesAnnals of Neurology, 2011
- Mesenchymal stem cells as trophic mediatorsJournal of Cellular Biochemistry, 2006